View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, Nov. 30 (HealthDay News) -- For obese men, supplementation with resveratrol, a compound found in red wine, is not associated with improvements in insulin sensitivity, blood pressure, or body composition, according to a study published online Nov. 28 in Diabetes.
Noting that, in animal and in vitro studies, resveratrol reverts metabolic risk factors, Morten M. Poulsen, M.D., from the Aarhus University Hospital in Denmark, and colleagues randomly assigned 24 obese but otherwise healthy men to four weeks of resveratrol or placebo treatment. Before and after treatment, metabolic assessments, including glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp), were performed.
The researchers found that, in both groups, there was a nonsignificant deterioration in insulin sensitivity. There was no change in endogenous glucose production or the turnover and oxidation rates of glucose. There was also no effect of resveratrol supplementation on blood pressure; resting energy expenditure; lipid oxidation rates; ectopic or visceral fat content; or inflammatory and metabolic biomarkers.
"The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders," the authors write.
The study was partially funded by the Novo Nordisk Foundation.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top